Truncating mutations and homozygous deletions in the hSNF5/INI1/BAF47 subunit of human SWI/SNF complexes occur in most malignant rhabdoid tumors and some other malignancies. How loss of hSNF5 contributes to tumorigenesis remains unknown. Because the SWI/ SNF subunit BRG1 is required for RB-mediated cell cycle arrest, we hypothesized that hSNF5 deficiency disrupts RB signaling. Here we demonstrate that unlike BRG1, hSNF5 deficient cells retain functional RB since ectopic expression of either p16ink4a or a constitutively active form of RB (PSM -RB) led to cell cycle arrest. To determine how hSNF5 loss might contribute to tumorigenesis, we used a retrovirus to introduce hSNF5 into multiple deficient cell lines. In all cases, re-expression inhibited colony formation and induced cell cycle arrest characterized by a flattened morphology. Flow cytometry revealed that these cells accumulated in G 0 /G 1 . Importantly, arrested cells exhibited strong induction of p16ink4a, hypophosphorylated RB, and down-regulation of cyclin A, suggesting that hSNF5 signals upstream of RB to induce growth arrest. Co-expression of SV40 T/t abolished hSNF5-induced G 1 arrest and activation of RB. Likewise, HPV-16 E7 was sufficient to partially overcome cell cycle arrest. These results suggest that hSNF5 loss is not equivalent to BRG1/ BRM loss in human tumor cell lines. Furthermore, hSNF5-induced cell cycle arrest of deficient cells is mediated in part through activation of p16ink4a expression. These findings provide insight into mechanisms of hSNF5-mediated tumor suppression.
Introduction
Chromatin remodeling complexes regulate gene expression by modulating access of transcription factors to DNA. The evolutionary conserved SWI/SNF complexes disrupt histone-DNA interactions to regulate access of binding domains to transcription machinery (for reviews, see Kingston and Narlikar, 1999; Peterson and Workman, 2000; Vignali et al., 2000; Workman and Kingston, 1998) . Human SWI/ SNF complexes contain about 10 subunits including one of two catalytic subunits, brahma-related gene 1 (BRG1) or brahma (BRM), which are orthologues of yeast SWI2/SNF2-like ATPases (Wang et al., 1996) . Other subunits shared in all SWI/SNF complexes include BRG1 associated factors (BAFs) BAF170, BAF155, BAF53, and hSNF5/INI1/BAF47 Sif et al., 2001; Xue et al., 2000) . It is unclear how many mammalian genes are regulated by SWI/ SNF, but recent studies demonstrate that the complex can mediate both activation and/or repression of approximately 5% of yeast genes (Holstege et al., 1998; Sudarsanam et al., 2000) .
The significance of SWI/SNF in the etiology of human neoplasia has only recently emerged. The hSNF5 subunit behaves as a bona fide tumor suppressor gene. Germline hSNF5 mutations result in the development of familial renal and extra-renal rhabdoid tumors and CNS tumors (Sevenet et al., 1999b; Taylor et al., 2000) . In addition, biallelic loss of expression mutations in this subunit occur in the majority of sporadic renal and extra-renal rhabdoid tumors suggesting its loss is a critical determinant in the development of most, if not all, rhabdoid malignancies (Biegel et al., 1999; DeCristofaro et al., 1999; Sevenet et al., 1999a; Versteege et al., 1998) . Similar loss of expression mutations in hSNF5 have been reported at a lower frequency in choroid plexus carcinoma (Sevenet et al., 1999a) . Other SWI/SNF complex members altered in human tumors are BRG1 and BRM, which are mutated or down-regulated in approximately 10% of human cancer cell lines Reisman et al., 2002; Strobeck et al., 2002; Wong et al., 2000) .
Targeted disruption of SWI/SNF alleles in mice have underscored a role for SWI/SNF in neoplastic processes. Three groups have independently demonstrated that mSNF5 +/7 mice develop tumors with features closely resembling human rhabdoid tumors (Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000) . As expected, molecular analysis of these tumors revealed loss of mSNF5 expression from the remaining wild-type allele. BRG1 +/7 mice develop subcutaneous glandular tumors that resemble breast adenocarcinomas (Bultman et al., 2000) . Although BRM 7/7 mice do not develop a tumor phenotype, they are heavier than control mice, and isolated embryonic fibroblasts show defects in G 0 /G 1 checkpoint controls (Reyes et al., 1998) .
The mechanism by which loss of hSNF5 contributes to neoplastic transformation remains unknown. In yeast, inactivation of any SWI/SNF component yields similar phenotypes (Laurent et al., 1991; Peterson and Herskowitz, 1992) . If the same was true in mammalian cells, hSNF5 loss, in principle, might be similar to BRG1 and BRM deficiency. Several studies have demonstrated that loss of expression of BRG1 and BRM proteins disrupts retinoblastoma (RB) function, a protein critical for cell cycle regulation. Both BRG1 and BRM bind RB and cooperate in RB-mediated growth suppression and repressor activity (Dunaief et al., 1994; Reisman et al., 2002; Strobeck et al., 2000b Strobeck et al., , 2002 Strober et al., 1996; Trouche et al., 1997; Zhang et al., 2000) . SW13 and C33A cells, which show little or no expression of BRG1 and BRM, are resistant to growth inhibition induced by ectopic expression of either p16ink4a, which activates RB, or a constitutively active mutant RB (PSM -RB) Strobeck et al., 2000b Strobeck et al., , 2002 . In these studies, coexpression of either BRG1 or BRM rescues RBmediated cell cycle arrest. Furthermore, BRG1 is required for RB to repress expression of cyclins E and A and cdc2, gene products critical for both G 1 /S and G 2 /M transitions (Strobeck et al., 2000b; Zhang et al., 2000) . It has also been shown that stable reexpression of BRG1 or BRM in SW13 cells leads to growth arrest which is dependent upon interaction of these proteins with functional RB (Dunaief et al., 1994; Strober et al., 1996) . Collectively, these data suggest that inactivation of BRG1/BRM (and thus SWI/SNF) renders cells resistant to RB-mediated growth regulation.
Whether inactivation of hSNF5 in tumors also disrupts RB function remains undetermined. Therefore, in this study we analysed whether hSNF5 deficient tumor cells remain responsive to RB-mediated growth inhibition. In addition, since it is not known how hSNF5 regulates cellular proliferation and why loss leads to tumorigenesis, effects on growth and cell cycle were characterized following re-expression of hSNF5 in deficient cell lines. We find that, unlike BRG1/BRM, RB does not require hSNF5 to mediate cell cycle arrest. However, we demonstrate that re-expression of hSNF5 suppresses growth by influencing specific G 1 /S regulatory factors, including p16ink4a and RB. Oncoproteins that disrupt G 1 /S checkpoints specifically inhibited hSNF5-mediated cell cycle arrest, supporting this finding. Our findings indicate that the functional consequences of hSNF5 and BRG1/BRM loss in tumor cells are not equivalent. In addition, we suggest that regulation of p16ink4a expression might represent a mechanism by which hSNF5 exerts its tumor suppressor functions.
Results

hSNF5 is dispensable for RB mediated cell cycle arrest
Expression of a dominant negative BRG1 mutant which lacks the ATPase activity required for SWI/ SNF-dependent chromatin remodeling activities is sufficient to block RB-mediated cell cycle arrest (Strobeck et al., 2000b) . This suggests that SWI/SNF complex activity, in addition to BRG1 expression, might be required for RB function. Since hSNF5 is a core component of SWI/SNF complexes, we hypothesized that loss of hSNF5 might yield defects in RB function, which may explain hSNF5's tumor suppression abilities. This notion is supported by work in yeast which has demonstrated that inactivation of any component of the SWI/SNF complex yields similar phenotypes (Laurent et al., 1991; Peterson and Herskowitz, 1992) . To address this question we first examined expression of RB pathway components, reasoning that a functional defect might lead to deregulation of RB signaling constituents. Western analysis of RB and cyclin D1 in seven hSNF5 deficient cell lines revealed apparently normal RB protein levels and no obvious cyclin D1 amplification (Figure 1a) . p16ink4a, which is not expressed in most normal tissues, was also very low and only detectable after long exposures in all cell lines. In contrast, HeLa cells which have compromised RB function due to expression of HPV-18 E7, demonstrated reduced RB protein levels and strong expression of p16ink4a. Therefore, we did not observe any obvious indications of RB dysfunction in hSNF5 deficient cell lines, suggesting that hSNF5 loss has no effect on RB function.
To directly assess the effect of hSNF5 deficiency on RB function we transiently expressed either p16ink4a or PSM -RB in three hSNF5 deficient cell lines: G401 and TM87-16, which are derived from malignant rhabdoid tumors, and A204, which was originally classified as an alveolar rhabdomyosarcoma, but which has recently been reclassified as an undifferentiated sarcoma (T Triche, personal communication). As a control, BRG1/BRM deficient SW13 cells, which are resistant to p16ink4a and PSM -RB, were also analysed. p16ink4a specifically activates endogenous RB by blocking cdk4/6 activity (Koh et al., 1995; Lukas et al., 1995; Serrano et al., 1993) . PSM -RB is a constitutively active phosphorylation site mutant RB which is insensitive to CDK-mediated inactivation (Knudsen and Wang, 1997) . Concordant with previous work (Strobeck et al., 2000b; Zhang et al., 2000) , SW13 proved essentially resistant to exogenous expression of either p16ink4a or PSM -RB as measured by BrdU incorporation (Figure 1b) . However, each of the three hSNF5 deficient cells were efficiently growthsuppressed by both p16ink4a and PSM -RB. Thus, unlike BRG1, hSNF5 is not required for RB-mediated 
hSNF5 is not required for CD44 expression
To assess the requirement for hSNF5 in another BRG1/ BRM regulated event, we analysed hSNF5 deficient cells for CD44 expression. Previous studies have demonstrated that BRG1 and BRM regulate expression of CD44, a membrane glycoprotein involved in cell adhesion and metastasis Strobeck et al., 2001 Strobeck et al., , 2002 . Cell lines which are deficient or contain reduced levels of BRG1 and BRM lack CD44 protein, and introduction of either BRG1 or BRM induces CD44 expression. To determine if hSNF5 loss also correlates with loss of CD44, hSNF5 deficient cells were examined for CD44 protein expression by Western blot. While four out of seven cell lines lack CD44, three (TM87-16, TTC642, A204) expressed considerable levels indicating that hSNF5 loss is not sufficient for CD44 down-regulation ( Figure 1c ). Together, these data suggest that hSNF5 loss is not equivalent to BRG1/ BRM loss since hSNF5 deficient cells are sensitive to RB and can express CD44.
hSNF5 induces growth arrest and flat cell formation of deficient cell lines
We and others have identified hSNF5 truncating mutations and homozygous deletions in most rhabdoid tumors and a subset of other malignancies (Biegel et al., 1999; DeCristofaro et al., 1999; Sevenet et al., 1999a; Versteege et al., 1998) . However, the mechanism behind hSNF5-mediated tumor suppression is not known. To begin to understand how hSNF5 loss contributes to tumor development we sought to determine the effects of introduction into several deficient cell lines. Initial experiments demonstrated that while exogenous expression of hSNF5 had no proliferation effects in hSNF5 positive SW13 cells, transient expression induced rapid cell cycle arrest of both TM87-16 and A204 ( Figure 2a ). Within 48 h, hSNF5 reduced the percentage of BrdU positive cells from 80.0% (vector) to 19.1% (hSNF5) in TM87-16 and from 88.5% (vector) to 9.6% (hSNF5) in A204. This is consistent with other reports that re-introduction of tumor suppressor genes induces rapid growth arrest Dillar et al., 1990; Huang et al., 1988) . However, we could not eliminate the possibility that hSNF5-induced cell cycle arrest was an artifact attributable to high levels of expression induced by a CMV promoter-driven expression vector. Therefore, we utilized the LTR promoter-driven pBABE retroviral vector that we and others have determined to result in near-endogenous levels of expression ( Figure 4a ) (Morgenstern and Land, 1990; Sullivan et al., 2001) . Retrovirus carrying either the parental vector pBABE or pBABE-hSNF5 was used to infect four hSNF5 deficient cell lines or hSNF5 positive HT1080 fibrosarcoma cells. Stably expressing cells were selected in puromycin for 1 -2.5 weeks. Coomassie staining of plates revealed a severe reduction in colony formation in all hSNF5 deficient lines ( Figure 2b ). A limited number of breakthrough colonies appeared following hSNF5 infection in these dishes. We have cloned and propagated many of these in an attempt to generate cell lines that stably express hSNF5. However, Western analysis of these clones indicated that none expressed the hSNF5 transgene (representative screening Western blot shown in Figure 2c ). Within several days following selection, we noted the presence of a characteristic flat cell morphology in hSNF5 but not vector control infectants (Figure 2d ). This morphology is often associated with cellular senescence and is reminiscent of that seen following introduction of RB into RB deficient SAOS cells and following ectopic expression of p16ink4a in U20S cells (Dai and Enders, 2000; Jiang et al., 2000) . It is also notable that similar morphologies have been observed following introduction of BRG1 into deficient SW13 and ALAB cells (Dunaief et al., 1994 ; Shanahan et al., 1999; Wong et al., 2000) . We found that flat cells induced by hSNF5 persisted in culture for at least several weeks and demonstrated increased cellular motility and numerous stress fibers. In contrast, infection of hSNF5 positive HT1080 had no obvious effects on growth, morphology, or colony forming ability and were indistinguishable from vector control infectants. We also found that plasminogen activator inhibitor type-1 (PAI-1) was strongly induced by hSNF5 in A204 cells (Figure 3) . PAI-1, a senescenceassociated marker, is characteristically overexpressed in senescent fibroblasts (Goldstein et al., 1994; Mu and Higgins, 1995) . Collectively, these data indicate that expression of hSNF5 in deficient cells leads to rapid cell cycle arrest accompanied by morphologic and biochemical features of senescence. Exogenous expression in hSNF5 positive cells has no effect on growth indicating that hSNF5 growth suppressive effects are specific to tumor cells which have lost its expression.
Stable re-expression of hSNF5 induces p16ink4a expression and activates RB
To gain insight into the mechanism of hSNF5-mediated growth suppression, we examined protein levels of cyclins, cyclin-dependent kinases (Cdk), and Cdk inhibitors following re-expression of hSNF5. A204 was infected with either vector control or hSNF5 retrovirus, and total protein was extracted for Western analysis following 13 days of selection. Retroviral infection of hSNF5 resulted in physiological levels of expression when compared to endogenous protein levels in HeLa (Figure 4a ). While we saw no change in cyclin E, cyclin D1, Cdk4, or p21waf1 levels, hSNF5 induced a dramatic increase in p16ink4a in A204 cells (Figure 4b ). We also observed a shift of RB to its active/hypophosphorylated form and a loss of cyclin A and Cdk2. p16ink4a is known to trigger an accumulation of hypophosphorylated RB by inhibiting Cdk4/6 activity (Koh et al., 1995; Lukas et al., 1995; Serrano et al., 1993) . As a result, hypophosphorylated RB blocks E2F transcriptional activation of S phase genes, including cyclin A (Alevizopoulos et al., 1997; Dyson, 1998; Knudsen et al., 1998 Knudsen et al., , 1999 Strobeck et al., 2000a; Zhang et al., 2000) . Cdk2 has also previously been reported to be down-regulated during RBmediated cell cycle inhibition (Strobeck et al., 2000a) .
Re-expression of hSNF5 induces G 0 /G 1 arrest p16ink4a induces G 1 arrest in an RB dependent manner (Lukas et al., 1995; Medema et al., 1995) . Furthermore, decreases in levels of hyperphosphorylated RB, cyclin A, and Cdk2 activity are characteristic features of G 1 arrest (Dulic et al., 1993; Serrano et al., 1997) . Thus, if up-regulation of p16ink4a was responsible for hSNF5-mediated cell cycle arrest, we would predict hSNF5 to also induce G 1 arrest. To test this hypothesis, we cotransfected GFP with either p16ink4a, hSNF5, or vector control into both TM87-16 and A204 to analyse by flow cytometry. Forty-eight hours after transfection, cells were harvested and the DNA content of gated GFP positive cells was determined. As predicted, we found that p16ink4a increased the fraction of cells in G 0 /G 1 in both TM87- Figure 4 Re-expression of hSNF5 induces p16ink4a expression leading to activation of RB. A204 was infected with either pBABE (vector) or pBABE -hSNF5 retrovirus and selected in puromycin. Total protein was harvested, separated by SDS -PAGE, and immunoblotted for (a) hSNF5 (b) various cell cycle proteins. Uninfected HeLa cell extract is included in (a) to show that pBABE -hSNF5 produced near-endogenous hSNF5 protein levels Figure 3 hSNF5-mediated induction of plasminogen activator inhibitor type-I (PAI-1), a senescence-associated marker. A204 was transfected by lipofectamine with either pBABE or pBABE -hSNF5. Twenty-four hours post-transfection, cells were placed under selection in 2.5 mg/ml puromycin and 3.5 days later, total protein was extracted, resolved by SDS -PAGE, and immunoblotted for the indicated proteins. BRG1 serves as a loading control hSNF5 induces G 1 arrest BL Betz et al 16 and A204 concurrent with a loss of S phase and cells in G 2 /M ( Figure 5 ). Transfection of hSNF5 induced an almost identical profile. While we observed a reduction, neither p16ink4a nor hSNF5 induced a complete loss of the G 2 /M population. However, this might be the result of a tetraploid population in A204 which would contain 4N DNA in G 0 /G 1 . It is unclear whether TM87-16 also contains tetraploid cells. Nevertheless, it appears that expression of hSNF5 in these deficient cell lines initiates G 1 arrest by inducing p16ink4a expression.
SV40 T/t antigens abolish hSNF5 mediated G 1 cell cycle arrest and activation of RB
The results presented in Figures 4 and 5 indicate that hSNF5 re-expression is characterized by RB activation and G 1 arrest. Therefore, we asked whether oncoproteins that bypass G 1 /S checkpoints might drive S phase progression in the presence of hSNF5. We utilized SV40 large T and small t antigens (pRNS-1) which are known to inhibit p53 and RB (Litzkas et al., 1984) . pRNS-1 was co-expressed with either p16ink4a or hSNF5 along with pH2B -GFP and cells were analysed by flow cytometry. We found that transfection of pRNS-1 alone substantially increased S phase and G 2 /M fractions compared to vector control in A204 (Figure 6a ). However, pRNS-1 was sufficient to overcome the G 1 block imposed by both p16ink4a and hSNF5, resulting in a cell cycle profile similar to pRNS-1 alone.
To confirm these observations, we examined expression of cell cycle proteins during co-expression of pRNS-1 and hSNF5. A204 was transiently transfected with either pBABE, pBABE-hSNF5, or p16ink4a along with pRNS-1 or vector and rapidly selected in puromycin for 3.5 days, then total protein was isolated and analysed by Western blot. Similar to stable expression of hSNF5 by retrovirus (Figure 4 ), transient expression of hSNF5 induced p16ink4a significantly, leading to accumulation of active/hypophosphorylated RB and attenuation of cyclin A (Figure 6b ). Exogenous expression of p16ink4a alone led to similar effects, and appeared to suppress cyclin A slightly more efficiently than hSNF5 in this assay. Co-expression of Figure 5 Accumulation of cells in G 1 following hSNF5 re-expression. Equivalent numbers of TM87-16 or A204 cells were plated in triplicate and cotransfected the following day with GFP expression plasmid and plasmids encoding either vector, p16ink4a, or hSNF5. After 48 h, the asynchronously growing cultures were fixed and then stained with propidium iodide. At least 2500 gated GFP positive cells were analysed for DNA content using flow cytometry. Representative profiles of cell number plotted versus DNA area are shown. Cell cycle distributions are averages of two independent experiments 6 SV40 T/t overrides hSNF5-induced G 1 block and activation of RB. (a) A204 was cotransfected with plasmids encoding either vector, pCG -hSNF5, or p16ink4a and either vector or pRNS-1 (SV40 T/t antigens) along with GFP expression plasmid. Forty-eight hours later, cells were fixed, stained with propidium iodide, and the DNA content of GFP positive cells analysed by flow cytometry. Representative profiles of cell number plotted versus DNA area are shown for one of two independent experiments. (b) A204 was cotransfected with either pBABE, pBABE -hSNF5, or p16ink4a expression vectors along with pRNS-1 where indicated at a 1 : 1 ratio. Transfections received equal amounts of puromycin-resistance plasmid and the total quantity of DNA was adjusted to equivalence with pBluescript SK+ plasmid. Twentyfour hours post-transfection, cells were placed under selection in 2.5 mg/ml puromycin. After 3.5 days of selection, total protein was extracted, separated by SDS -PAGE, and immunoblotted for the indicated proteins. Untransfected hTert-immortalized fibroblasts (NHF) and HeLa cell extracts are included for reference. 'NS' denotes nonspecific bands recognized by the polyclonal hSNF5 antisera and serve as loading controls hSNF5 induces G 1 arrest BL Betz et al pRNS-1 with either hSNF5 or p16ink4a effectively restored phosphorylation of RB and cyclin A expression, even in the presence of significant p16ink4a levels. These data indicate that oncoproteins that bypass G 1 /S regulation allow cell proliferation following hSNF5 reexpression.
HPV-16 E7 partially rescues A204 from hSNF5 mediated arrest
Next we tested the ability of E7 to block hSNF5-mediated cell cycle arrest. Like SV40 large T antigen, HPV E7 binds and sequesters pocket proteins (Munger et al., 2001) . Because our results suggest that hSNF5 signals upstream of RB, through activation of p16ink4a expression, we hypothesized that E7 might drive S phase progression in the presence of hSNF5. A204 was transiently transfected as in Figure 6a , but with HPV-16 E7 rather than pRNS-1. Cell cycle distribution was determined using flow cytometry ( Figure 7a ) and the S phase fraction of each transfection was graphed relative to vector control ( Figure 7b ). Unlike pRNS-1, expression of E7 alone had little effect on the per cent of cells in S phase compared to vector control (107.5% E7 vs 100% vector control) ( Figure 7b ). As expected, E7 significantly inhibited p16ink4a induced arrest (67.1% p16+E7 vs 33.4% p16). Intriguingly, we found that co-expression of hSNF5 with E7 consistently resulted in an increase in S phase fraction compared to hSNF5 alone (49.9% hSNF5+E7 vs 27.0% hSNF5). These results indicate that hSNF5-induced G 1 arrest is likely mediated in part through activation of p16ink4a expression and RB. However, it is possible that growth suppression induced by hSNF5 is regulated in part through other factors such as p107 and p130 which are also bound and inactivated by E7. These findings also indicate that hSNF5 signaling is presumably more complex than simply activation of p16ink4a expression since E7 is insufficient to fully reverse hSNF5-imposed arrest.
Discussion
Malignant rhabdoid tumors are rare, poorly understood, embryonal neoplasms characterized by clinical aggressiveness and resistance to chemotherapy. One feature that approximately 85% of all rhabdoid tumors share, regardless of anatomical site, is alteration of hSNF5 (Biegel et al., 2002) . Analysis of other tumors and tumor cell lines has revealed that loss of expression mutations occur at a lower frequency in a limited number of other tumors (DeCristofaro et al., 1999 Sevenet et al., 1999a,b) . Although it is apparent that hSNF5 loss plays a critical role in rhabdoid tumor development, it is less clear how it regulates cellular proliferation since little is known about its cellular targets. Because hSNF5 is a core component and present in all human SWI/SNF complexes identified to date Phelan et al., 1999; Sif et al., 2001; Xue et al., 2000) , inactivation of hSNF5 may be expected to alter SWI/SNF complex function and/or specificity. In support of this, of 10 SWI/SNF subunits identified in yeast, only three, including Snf5 and Swi2/Snf2, which are yeast homologs of human hSNF5 and BRG1, were shown to interact directly with DNA binding transcriptional activators (Neely et al., 2002) . It is suggested that these SWI/SNF components may function in the recruitment of SWI/SNF to specific promoters. Thus, one goal of this study was to contrast the functional consequences of hSNF5 loss with BRG1/BRM loss in tumor cells. The fact that hSNF5 7/7 and BRG1 7/7 mice are both embryonic lethal at the peri-implantation stage (approximately E3.5 -E6.5) suggests there might be functional overlap (Bultman et al., 2000; Guidi et al., 2001; KlochendlerYeivin et al., 2000; Roberts et al., 2000) . This is unlikely however, because the tumor phenotypes associated with the respective heterozygous mice are different. Furthermore, malignant rhabdoid tumors which have lost expression of BRG1 or any other SWI/SNF components besides hSNF5 have not been reported to date. In support of this, we show here that unlike BRG1/BRM, hSNF5 does not cooperate with RB to mediate cell cycle arrest and is dispensable for CD44 expression. These results indicate that hSNF5 is not required for all functions attributed to BRG1 and BRM (and thus the SWI/SNF complex). Why hSNF5 loss does not affect these functions is not clear. It is possible that BRG1/BRM cooperation with RB in cell cycle arrest and effects on CD44 expression occur independent of SWI/SNF complexes as a whole, or utilize only distinct subunits. Alternatively, hSNF5 might be required to direct the complex to only a subset of target promoters. This idea is supported by the finding that c-Myc binds hSNF5 to cooperate in transactivation of E box-containing promoters suggesting c-Myc-hSNF5 interactions might specifically recruit the SWI/SNF complex to c-Myc regulated genes (Cheng et al., 1999) .
It is noteworthy, however, that re-expression of hSNF5 in deficient cells induces features similar to those seen with introduction of BRG1 into BRG1/ BRM deficient SW13, C33A, and ALAB cells. For example, stable re-expression of BRG1/BRM in deficient tumor cell lines reduces colony formation and induces flat cell formation with a senescent phenotype (Dunaief et al., 1994; Shanahan et al., 1999; Strober et al., 1996; Wong et al., 2000) . In addition, re-expression of BRG1 in deficient cells restores RB-mediated down-regulation of cyclin A and Cdk2, while leaving cyclin E and Cdk4 unaffected (Strobeck et al., 2000a,b) . This is consistent with what has been observed following introduction of PSM -RB into SAOS-2 cells, which also leads to a G 1 block characterized by attenuation of cyclin A and Cdk2 without affecting cyclin E and Cdk4 (Strobeck et al., 2000a) . Another similarity to our findings is that BRG1/BRM mediated cell cycle arrest is inhibited by pocket binding oncoproteins including E1A (Dunaief et al., 1994; Strober et al., 1996) . Collectively these findings underscore the significance of RB in mediating SWI/SNF-imposed G 1 cell cycle arrest.
The morphologic and biochemical features of hSNF5 arrested cells closely resemble those observed during cellular senescence, an irreversible growth arrest induced by cumulative cell divisions (Smith and Pereira-Smith, 1996; Stein and Dulic, 1995) . Characteristic features of senescence include cell flattening, a failure to proliferate in the presence of growth factors, and overexpression of PAI-1 (Goldstein et al., 1994; Mu and Higgins, 1995; Robbins et al., 1970) . Senescent cells also arrest with G 1 DNA content and express increased levels of p16ink4a leading to accumulation of hypophosphorylated RB (Alcorta et al., 1996; Stein et al., 1990) . Similarly, like hSNF5 induced growth arrest, senescent fibroblasts down-regulate both cyclin A and cdk2 while maintaining expression of cyclin D and cyclin E (Afshari et al., 1993; Dulic et al., 1993; Lucibello et al., 1993; Morisaki et al., 1999) . In support of this, RB-induced senescence in SAOS-2 cells is associated with dose dependent RB-mediated downregulation of cyclin A and Cdk2 (Jiang et al., 2000) . In addition to cumulative cell divisions, it has been suggested that cellular senescence may occur in response to oncogenic or strong mitogenic stimuli. For example, DNA damage, altered DNA methylation levels, and overexpression of E2F1 or activation of Ras -Raf -Mek signaling have all been shown to induce cellular senescence (Campisi, 2001) . It is possible that hSNF5 deficiency prevents cells from efficiently signaling to p16ink4a to withdraw from the cell cycle in response to one of these signals. Indeed, all hSNF5 deficient cell lines we examined demonstrated very little detectable p16ink4a. Thus, re-expression of hSNF5 in rhabdoid cells might activate or restore a senescence signal through one of these pathways.
If activation of p16ink4a expression and RB underlies hSNF5-mediated cell cycle arrest, then E7 should completely inhibit hSNF5 cell cycle arrest. We found that E7 was less efficient in overcoming hSNF5-imposed cell cycle arrest compared to p16ink4a-induced arrest. Thus, hSNF5-induced arrest appears more complex than simply up-regulation of p16ink4a. It is possible that the increased p16ink4a expression we observed is an indirect effect, and not the primary growth arrest signal, but the result of the cells undergoing a senescence program. However, we have observed a substantial increase in p16ink4a in less than 48 h following transfection of hSNF5 which argues against this presumption (data not shown). We have observed this in both A204 and TM87-16, demonstrating that these effects are not limited to A204. Despite this, hSNF5-mediated induction of p16ink4a expression is functionally significant since ectopic expression of p16ink4a alone is sufficient to induce arrest in these cells. Our finding that all hSNF5 deficient cells lack significant p16ink4a levels also underscores their sensitivity to the growth suppressive effects of p16ink4a. We found that p16ink4a was detectable in all seven hSNF5 deficient cells by Western blot, but only after long exposures. This indicates that the absence of p16ink4a expression in these cells is due to reduced transcription and not gene deletion.
It is not clear how hSNF5 signals to activate p16ink4a expression. Recently, the finding that the polycomb group protein Bmi-1 represses p16ink4a expression in mice has shed light on p16ink4a regulation (Jacobs et al., 1999) . Similarly, Id1 functions to repress p16ink4a expression, which is opposed by the activating effects of Ets1 and Ets2 (Alani et al., 2001; Ohtani et al., 2001) . JunB has also been shown to activate the p16ink4a promoter directly through three AP1-like binding sites (Passegue and Wagner, 2000) . Intriguingly, JunB binds the BAF60a subunit of the mammalian SWI/SNF complex (Ito et al., 2001) . This suggests that the SWI/SNF complex might be recruited directly to the p16ink4a promoter. Whether hSNF5 activates p16ink4a by modulating one of these mechanisms remains to be determined. Alternatively, hSNF5 could alter patterns of methylation at the p16ink4a promoter, which is frequently silenced through methylation in various tumors.
The RB growth suppressing pathway is thought to be inactivated in almost all tumors. This may be accomplished through multiple mechanisms including expression of oncoproteins, overexpression of cyclin D/ Cdk4, loss of p16ink4a, or direct mutation of RB itself (Bartek et al., 1997; Sherr, 1996) . It is tempting to Versteege et al., 1998) . TTC549, TTC642, TM87-16, and G401 have been described in more detail elsewhere (Garvin et al., 1993; Karnes et al., 1991; Ota et al., 1993; Peebles et al., 1978; Suzuki et al., 1997) . Cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum at 378C in 5% CO 2 . A 1.8 kb cDNA encoding the full-length longer splice variant hSNF5 was cloned into the EcoRI site of pBluescript SK+ (Stratagene) from pCG -hSNF5 (gift of Dr W Wang, National Institute of Health, Baltimore, Maryland, USA), then cloned into the BamHI and SalI sites of pBABE -puro to generate pBABE -hSNF5. pBABE -puro and PSM -RB have been previously described (Knudsen and Wang, 1997; Morgenstern and Land, 1990) . Expression constructs pCMV -p16ink4a, pRNS-1 (containing an origin-defective SV40 genome), and p1225 E7 (encoding HPV-16 E7) were gifts of Dr Y Xiong (University of North Carolina), Dr H Ozer (New Jersey Medical School), and Dr P Howley (Harvard Medical School) respectively. pH2B -GFP encoding GFP linked to histone 2B was obtained from Dr G Wahl (Salk Institute). Plasmids were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Retroviral infections
Briefly, 9610 6 293 cells were plated into 10 cm tissue culture dishes. The following day cells were transfected by calcium phosphate method (Gibco BRL) with 5 mg pVSVG, 5 mg pGag-pol (gifts from Dr L Su, University of North Carolina), and 10 mg of either pBABE -puro or pBABE -hSNF5. After 8 h, the transfection medium was aspirated and 10 ml DMEM-H+10% FBS was added. Sixteen hours later, cells were fed with 10 ml DMEM-H with 10% FBS. After 24 h the virus-containing media was collected and centrifuged at 500 g to remove contaminating 293 cells. Viral supernatant was diluted 1 : 5 in RPMI 1640 containing 10% FBS and polybrene (8 mg/ml). Five ml of the retroviral solution was overlaid on the recipient cells, which were 40 -60% confluent in 10 cm dishes at the time of infection. After a 4 h incubation, the infection medium was replaced with 10 ml RPMI 1640+10% FBS. The following day, cells were split into 10 cm dishes. Twenty-four hours later, the growth medium was changed to RPMI 1640 supplemented with 10% FBS and either 1.0 mg/ml (A204), 1.1 mg/ml (TTC642),1.25 mg/ml (HT1080), or 1.5 mg/ml (TTC549, TM87-16) puromycin. Stable infectants were maintained under puromycin selection for their duration of culture. One to 2.5 weeks later, colonies were fixed and stained (50% methanol, 10% glacial acetic acid, 1 g/l Coomassie blue).
Immunoblotting
Subconfluent cultures were trypsinized, collected in complete media, and washed twice in PBS. Total protein was extracted using 8 M urea (8 M urea, 0.1 M NaH 2 PO 4 , 10 mM Tris pH 8) as previously described . Equal amounts of lysates were then separated via SDS-polyacrylamide gel electrophoresis (either 7.5% or 4 -20%) and transferred onto Immobilon-P (Millipore) by standard methods. Membranes were incubated with either of the following antibodies: CD44 (Hermes 3, Dr L Sherman, University of Cincinnati College of Medicine), Cdk4 (H-22, Santa Cruz), Cdk2 (M-2, Santa Cruz), cyclin A (H-432, Santa Cruz or 6E6, Novocastra), cyclin D1 (Ab-3, Neo-markers or R-124, Santa Cruz), cyclin E (C-19 or M-20, Santa Cruz Biotechnology), p21waf1 (H-164, Santa Cruz or AB-1, Oncogene Research Products), p16ink4a (H-156, Santa Cruz or G175-1239, Pharmingen), RB (851, Dr J Wang, University of California, San Diego or G3-245, Pharmingen), polyclonal anti-PAI-1 (Molecular Innovations), polyclonal anti-hSNF5 (Dr W Wang, National Institute of Health or Dr A Imbalzano, University of Massachusetts Medical School), or BAF53 (Dr W Wang). Blots were then incubated with horseradish peroxidase conjugated anti-rabbit or anti-mouse IgG (Amersham) for 1 h. Blots were detected with ECL chemiluminescense reagent (Amersham) on Biomax ML film (Kodak).
BrdU incorporation
Cells were seeded in 6-well plates on glass cover slips (Corning) prior to transfection. At 20 -40% confluence, cells were cotransfected with 5 mg pCDNA3, pCMV -p16, PSM -RB, or pCG -hSNF5 and 0.35 mg pH2B -GFP. After 48 h, cells were labeled with 3 mg/ml bromodeoxyuridine (BrdU) (Amersham) for an additional 24 h, then fixed with 90% icecold ethanol and 5% glacial acetic acid for 30 min. BrdU incorporation was detected using monoclonal anti-BrdU antibody (Amersham) and Alexa Fluor 546 anti-mouse IgG secondary antibody (Molecular Probes). At least 200 transfected cells identified as GFP positive were scored for BrdU incorporation by fluorescent microscopy (Zeiss Axioscope).
Flow cytometry
1.2610
6 A204 or 1.8610 6 TM87-16 cells were seeded in T25 flasks 1 day prior to transfection. For these experiments, a subclone of A204 was developed. Double vector transfections ( Figure 5 ) used 8.4 mg pcDNA3, pCG -hSNF5, or pCMVp16 along with 1.7 mg pH2B -GFP. Triple transfections (Figures 6a and 7) used 5 mg pcDNA3, pCG -hSNF5, or pCMV -p16 and 5 mg pcDNA3, pRNS-1, or p1225 E7 along with 0.8 mg pH2B -GFP. Forty-eight hours post-transfection cells were trypsinized, washed in PBS, fixed in 70% ethanol, then stained with propidium iodide solution (20 mg/ml propidium iodide (Molecular Probes), 200 mg/ml RNase A (Sigma), 0.1% Triton X-100 (Sigma) in PBS). At least 2500 gated GFP positive cells were analysed for DNA content on a FACScan flow cytometer (Becton Dickinson). Cell cycle distribution was determined using ModFit LT software (Verity).
